...
首页> 外文期刊>Urology >Emphysematous pyelonephritis: outcome of conservative management.
【24h】

Emphysematous pyelonephritis: outcome of conservative management.

机译:气肿性肾盂肾炎:保守治疗的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To identify the prognostic factors, assess the outcome of conservative management, and modify the existing radiologic classification of emphysematous pyelonephritis. METHODS: Forty-one consecutive patients diagnosed with emphysematous pyelonephritis between January 2001 and February 2007 were studied retrospectively. On the basis of computerized tomographic scan they were grouped into four classes (1 to 4). The management was conservative with antibiotics alone or with a combination of percutaneous drainage and antibiotics. RESULTS: Thirty-eight (93%) of a total of 41 patients were diabetic. Escherichia coli (in 97%) was the predominant pathogen identified in pus culture. With antibiotics alone treatment was successful in 40%, and with a combination of percutaneous drainage and antibiotics the success rate was 80%. None underwent nephrectomy as a primary procedure. The risk factors for mortality were thrombocytopenia, shock, altered sensorium, and hemodialysis. In the absence of risk factors the success rate with conservative management was 100%. The mortality rate was 27%, 75%, and 100% in the presence of one, two, and three risk factors, respectively. The mortality rate in class 1, 2, 3, and 4 was 9%, 13%, 50%, and 33% respectively. The overall success rate was 78%. CONCLUSIONS: A combination of percutaneous drainage with antibiotics offers an effective therapy for emphysematous pyelonephritis.
机译:目的:确定预后因素,评估保守治疗的结果,并修改现有的肺气肿性肾盂肾炎的放射学分类。方法:回顾性分析2001年1月至2007年2月间共41例被诊断为气肿性肾盂肾炎的患者。在计算机断层扫描的基础上,将它们分为四类(1-4)。单独使用抗生素或结合经皮引流和抗生素进行保守治疗。结果:41名患者中有38名(93%)为糖尿病患者。大肠杆菌(占97%)是脓液培养中鉴定出的主要病原体。单独使用抗生素治疗成功率为40%,而经皮引流和抗生素相结合的成功率为80%。没有人接受肾切除术作为主要手术。死亡的危险因素是血小板减少,休克,感觉觉改变和血液透析。在没有风险因素的情况下,保守治疗的成功率为100%。存在一种,两种和三种危险因素时,死亡率分别为27%,75%和100%。第1、2、3和4类的死亡率分别为9%,13%,50%和33%。总体成功率为78%。结论:经皮引流与抗生素结合可为​​气肿性肾盂肾炎提供有效的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号